iPSCs
Cell Lines
Revolutionize Advanced Therapies
with NYBCe’s Cutting-Edge iPSC Innovations
Diverse
Starting Materials
NYBCe, a distinguished leader in cell therapy research, has made a groundbreaking advancement within our National Cord Blood Program. We have discovered a unique subset of HLA homozygous cord blood units, now ethically consented for advanced therapy development, unlocking new possibilities in cell and gene therapies.
Reflecting the rich diversity of our country, these cord blood units provide a highly versatile and invaluable resource for developing allogeneic iPSC-derived cell therapies.
Start Your Partnership
Partner with NYBCe to harness the potential of homozygous Research or GMP-grade iPSC lines as the foundation for your next breakthrough therapy.
Connect with the NYBCe Haplobank team today to learn more.